It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez
Read the interview with the Nepal Live Today – October 21, 2024.
Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award
The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!
Pat is one of three finalists for this year’s award, alongside two friends and compatriots in the fight against cancer: Asem Mansour of King Hussein Cancer Center in Jordan, and Wondu Bekele Woldemariam of Mathiwos Wondu-YeEthiopia Cancer Society. Our thanks and congratulations go out to all three finalists for their tremendous impact and visionary leadership. The world is a better place for their contributions.
We would also like to thank the 18 different Patient Associations from around the world that sent letters in support of Pat’s nomination. You are the inspiration for all we do and we are so very grateful for your support.
The winner of the award will be announced on October 2nd at this year’s World Cancer Congress in Kuala Lumpur. Representatives from The Max Foundation and patient advocates from across Asia will be in attendance to share their knowledge, their experiences, and, of course, to cheer on Pat!
Visit the UICC website to learn more about the awards and the finalists.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
Welcoming two new members to our Strategic Innovation Advisory Board
Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD join the board this March
The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….